Measurement of intracellular calcium release following agonist challenge within cells expressing the relevant membrane protein is a commonly used format to derive structure-activity relationship (SAR) data within a compound profiling assay. The Fluorometric Imaging Plate Reader (FLIPR) has become the gold standard for this purpose. FLIPR traditionally uses cells that are maintained in continuous culture for compound profiling of iterative chemistry campaigns. This supply dictates that assays can only be run on 4 of 5 weekdays, or alternative cell culture machinery is required such that plating can occur remotely at the weekend. The data reported here demonstrate that high-quality compound profiling data can be generated from the use of cryopreserved cells and that these cells can also be plated at various densities to generate equivalent data between 24 and 72 h postplating. Hence, the authors report a method that allows data generation throughout the week and without the requirement of highly automated cell culture or continuous culture. (Journal of Biomolecular Screening 2008:354-362) 
INTRODUCTION
T HE ITERATIVE STRUCTURE-ACTIVITY RELATIONSHIP (SAR) process is pivotal to modern drug development and the pharmaceutical industry. The compound profiling capabilities demonstrated within this report, when combined with structural knowledge of the compounds studied, allow such iterative SAR to be derived. The success of such a campaign is dependent on the use of accurate, flexible, and reliable assays to measure functional ligand-receptor interactions. Thus, this provides biological knowledge to facilitate drug development. Where chemical modifications are made to improve the desired properties of the molecules being studied, new concepts, technologies, and assays are of great importance to increase the speed at which conclusive data can be generated. The work presented here summarizes the development of assays from cryopreserved cells, as well as its impact on scientists' ability to plan and schedule assays of varying size at short notice and reduce cell wastage.
The use of the Fluorometric Imaging Plate Reader (FLIPR) to measure intracellular calcium mobilization has been an integral part of high-throughput screening (HTS), orphan receptor screening, and structure-activity relationship profiling within the pharmaceutical industry for many years. [1] [2] [3] [4] [5] [6] [7] FLIPR is a very versatile technology, lending itself well to different methodologies and plate types. [8] [9] [10] This is a real-time in vitro pharmacology platform that measures intracellular calcium as an indication of target activation or inactivation. 3 This technology requires live cells that are usually maintained in continuous culture over a number of passages, which for compound profiling require strict timetabling and upfront knowledge of anticipated compound throughput to avoid overproduction. Although there are now literature reports of the use of cryopreserved cells within cellular assays, these are yet to be described as the preferred screening source for compound profiling across a large number of assays. 11, 12 In addition, in a normal working week, the continuous culture supply method dictates that assays can only be run on Tuesday through to Friday each week or requires complex and automated cell culture machinery, such as the SelecT, 13 so that cells can be plated over the weekend and will be ready to assay on Monday. The cryopreservation of cells as opposed to continuous culture allows a high-density fermentation to select cells from the same passage to be preserved ready for seeding into assay plates. This method has been reported to generate data that are more uniform than continuous culture, 14 although largely these benefits have been discussed in terms of their application to HTS support. In addition to demonstrating the application of cryopreseved cells to compound profiling assays over an extended time period, we have investigated plating these cells at differing densities depending on the intended utilization time, with the intent of demonstrating that equivalent pharmacology can be achieved over a prolonged time period, without the requirement of highly automated cell culture or continuous culture.
MATERIALS
All cell culture reagents were obtained from Gibco Invitrogen (Carlsbad, CA), unless otherwise stated. Fluo-4 and Brilliant Black were sourced from Molecular Devices (Sunnyvale, CA). All other reagents were from Sigma (St. Louis, MO) unless otherwise stated.
METHODS

Cell culture
For both continuous culture and growth of cells prior to cryopreservation, the following growth conditions were used. Adherent Chinese hamster ovary (CHO) cells stably expressing the recombinant human histamine H 1 receptor or the recombinant human motilin GPR38 receptor were maintained in culture at 37 °C under 5% CO 2 in alpha minimum essential medium without ribonucleosides supplemented with 10% dialyzed fetal bovine serum (FBS) and 200 mM glutamine. Split ratios for these cells were between 1:10 and 1:20 depending on cell growth rates and confluency.
Rat 1 fibroblast cells (American Tissue Culture Collection CRL-1378) stably expressing the human adrenergic alpha 1A receptor or the human adrenergic alpha 1B receptor were maintained in culture at 37 °C under 5% CO 2 in dialyzed minimum essential medium supplemented with 10% FBS and 200 mM glutamine.
Split ratios for these cell types were between 1:10 and 1:20 depending on cell growth rates and confluency.
Adherent SH-SY5Y (American Type Culture Collection CRL-2266) cells stably expressing recombinant human 5-HT 2A , 5-HT 2B , or 5-HT 2C were maintained in culture at 37 °C under 5% CO 2 in alpha minimum essential medium with ribonucleosides supplemented with 10% dialyzed FBS and 400 μg geneticin. Split ratios for these cell types were between 1:4 and 1:8 depending on cell growth rates and confluency.
Cell freezing protocol
Cells were harvested from adherent culture using standard procedures and resuspended in phosphate-buffered saline (PBS). The cells were counted using a Vi-Cell or Cedex cell counter to identify a total and viable cell count. They were then centrifuged at 300 to 400 g for 10 min at room temperature. The supernatant was aspirated and cells resuspended in dialyzed FBS (at 4 °C, such that they were at twice the desired final concentration,~5 × 10 7 cells/mL). An equal volume of freezing medium (20% DMSO/ 80% dialyzed FBS, prepared and prechilled) was then gradually added. This suspension was carefully mixed while it was divided into 1-mL aliquots that were subsequently frozen in a precooled, controlled-rate freezer. This was set to the following controlledrate freezing cycle: hold at 4 °C for 7 min, cool 1 °C per min to -5 °C, cool 3 °C per min to -12 °C, cool 5 °C per min to -14 °C, cool 7.5 °C per min to -20 °C, cool 6.5 °C per min to -25 °C, hold for 2 min at -25 °C, warm 3 °C per min to -20 °C, hold for 2 min at -20 °C, cool 1 °C per min to -50 °C, and cool 10 °C per min to -130 °C. Once complete, the cells were transferred to a -140 °C freezer for storage.
Cell seeding protocol
The method below describes the procedures used for all cell types. Seeding densities are shown for histamine and alpha 1A/1B cells. However, cell densities were adjusted accordingly to achieve final seeding densities of 16,000 cells/well for SH-SY-5Y cell lines and 10,000 cells/well for CHO GPR38 cells; note that these cell lines were not assessed at 72 h.
Cell vials were rapidly thawed by placing in a waterbath preheated to 37 °C with gentle agitation. The aliquot was then swabbed with 70% ethanol and allowed to air dry in a laminar flow cabinet. The cell suspension was then carefully transferred to a 50-mL centrifuge tube, and prewarmed (37 °C) culture medium was slowly added with mixing to resuspend the cells to a nominal concentration of 2 × 10 6 cells/mL. These were then centrifuged at 300 g for 5 min and the supernatant removed, to remove any residual DMSO, and were again resuspended in prewarmed (37 °C) culture medium at approximately 2 × 10 6 cells/mL. A total and viable cell count was performed using a Cedex cell counter, and the cells were resuspended at 2.4 × 10 5 cells/mL for 24-h testing or 8 × 10 4 cells/mL for 72-h testing. For 24-h and 72-h testing, cells were seeded into black-walled, clear-base 384-well plates at a density of 12,000 and 4000 cells/well (respectively) and cultured at 37 °C under 5% CO 2 .
For continuous culture, cells were also harvested from adherent culture using standard procedures and resuspended cell media at 2.4 × 10 5 cells/mL as for 24-h testing. They were then plated as described above for cryopreserved cells at 12,000 cells/well.
Measurement of intracellular Ca 2+ + concentration using the FLIPR
Following media aspiration, the cells were incubated with Hank's buffered salt solution (HBSS) medium (CaCl 2 ⋅2H 2 O 1.26 mM, glucose 5.55 mM, KCl 5.36 mM, MgS0 4 [anhyd] 0.81 mM, NaCl 136.89 mM, KH 2 P0 4 [anhyd] 0.41 mM, HEPES 20 mM, NaHC0 3 4.16 mM) containing the cytoplasmic calcium indicator, Fluo-4 dye in the acetylmethyl form (4 mM), 2.5 mM probenecid, and 250 μM Brilliant Black (Molecular Devices) at 37 °C for 60 min. The loaded cells were then incubated with test compound for 30 min at 37 °C. The plates were then placed into a FLIPR (Molecular Devices) for testing in antagonist mode, where a predetermined concentration of the relevant agonist, histamine or phenylepherine (4×EC 50 ), was added while cell fluorescence (λex 488 nm, λem 540 nm) was monitored. The 4×EC 50 value was selected as (assuming a slope of 1) this is equal to the EC 80 for the agonist and is at a position in the dose-response curve that will allow sensitive detection of agonist inhibition without significant risk of masking inhibition curves. In addition, the response size observed at 4×EC 50 is large, allowing robust and reproducible data generation. Data were converted into normalized florescence units by taking the peak height response, subtracting the baseline, dividing this response size by the baseline, and multiplying that value by 100. These data were further analyzed using a 4-parameter logistic fit in a Microsoft Excel spreadsheet environment. Functional pKi calculations were made using the agonist response data on the day and the equation below, assuming a slope of 1. Functional pKi = IC 50 /(1 + [EC 80 ]/EC 50 ), where IC 50 is the recorded 50% inhibition response of the antagonist under test, [EC 80 ] is the concentration of agonist that produces 80% maximum and the concentration of agonist used to stimulate activity during the test, and EC 50 is the 50% maximum response of the agonist used. Furthermore, Z′ was defined by the following equation: 1 -(3*SD L/3*SD H)/(Average H -Average L), where L is the low control values and H is the high control values.
Statistical methods for concordance correlation coefficient
Compound standard deviations (SD) were calculated for all compounds tested >7 occasions within a 6-month timeframe. Table 3 shows the mean (SD) generated.
Assay correlation data were analyzed statistically with the aid of a correlation tool that statistically evaluates both interassay accuracy and interassay precision by the use of a single statistic: the concordance correlation coefficient (CCC). The CCC is the multiplication of interassay precision and accuracy. Interassay precision is calculated as the deviation of the assay average of 1 assay from the other assay under perfect-match conditions. Interassay accuracy is deduced from Pearson's statistical correlation. Two assays are considered identical (perfect match) if the CCC value is greater than 0.81, 2 assays are considered related (good match) if the CCC value is between 0.81 and 0.64, and 2 assays are considered different (poor match) if the CCC is lower than 0.64.
RESULTS
All of the assays that we present here have been used within iterative compound profiling programs over a period of time in excess of 6 months using cryopreserved cells, with the exception of the 5HT2B assay (see supplemental figure at http://jbx.sagepub .com/supplemental). Figure 1 and Table 1 show exemplar data where training sets of compounds with known pharmacological profiles have been used to compare and validate the pharmacology of assays when sourced from cryopreserved cells. In each case, compounds were tested to at least an n of 5, and on at least 2 separate test occasions and in the majority of cases, this spans 4 test occasions. Detailed pEC 50 values for agonist ligands used in stimulation for antagonist assays or the natural ligand can be seen in Table 2 ; these data were generated over the current life span of the cryopreserved assay and an equivalent period for the data from continuous culture.
In addition, data quality was also assessed by measuring the variability of test compound data generated in each of these assays, on cells supplied from cryopreseved stocks. A subset of these assays is shown in Table 3 . This table also records the signal size in normalized florescence units and shows that in Interassay accuracy is measured as the deviation of the assay average of 1 assay from the other assay under perfect-match conditions (45-degree line). Interassay precision is calculated from Pearson's correlation. The concordance correlation coefficient is the multiplication of interassay precision and accuracy. It therefore measures both interassay accuracy and interassay precision at the same time. each case, the maximum values can be consistently and statistically determined from the baseline by the Z′ value for each cell type and enables comparison between cryopreserved cells and continuous culture. One of our aims for this work was to extend the utility and flexibility of Ca 2+ screening using the FLIPR by examining the capabilities of cryopreserved cells. In line with this, we examined the use of cryopreserved cells by plating them at differing densities for assay 72 h later. This allowed plating on a Friday and assay on a Monday. During assay development, cells were plated at 12,000, 6000, 4000, and 2000 cells/well and tested with simple agonist dose-response curves (data not shown). The H1-containing CHO cells required a plating density of 4000 cells/well to obtain data similar to high-density 24-h plating. Interestingly, however, the rat fibroblast cells were extremely robust and performed well at all densities; therefore, the 4000 cells/well density was chosen as this gave good signal and pharmacology, and it conserved frozen cell stocks. Using this approach, we have validated the use of cryopreserved cells within 3 compound profiling assays for use 72 h following cell plating. Table 3 and Figure 2 show data generated from the histamine H1 receptor assay. Over an interleaved time period, data were generated from low-density (4000 cells/well) 72-h plating and high-density (12000 cells/well) 24-h plating. Similar pharmacological equivalence and variance data were generated for the adrenergic alpha 1A ( Table 4 and 
DISCUSSION
To provide greater flexibility for cell-based compound profiling assays using the FLIPR technology, we have successfully transitioned a significant number of assays to be sourced from cryopreserved cells rather than from continuous culture. Figure 1 and Table 1 demonstrate that these transitions were made while maintaining statistically perfect correlations of pharmacology. The use of a large training set of ~20 compounds in each case and statistical assessment adds confidence to the relatively low assay occasion (a total of at least 5 data points for each compound generated over 2, 3, or 4 test occasions). In 6 of the 7 assays shown, there is a reduction in mean pEC 50 in cryopreserved cells of the agonist used to stimulate responses in antagonist assays, but these reductions are generally small or are observed within assays run in the antagonist mode where agonist variance is controlled for by EC 80 stimulation. This also indicates the requirement for multiple standards in each assay format such that broad comparisons of pharmacology can be made, as is the case for data within Table 1 and the overall conclusion of equivalence.
These data demonstrate that the cryopreservation procedure generates assays with similar variance (assessed by standard deviation, Table 3 ) over an extended period, with 6 assays becoming slightly more variable and 4 assays becoming slightly All data were generated using cryopreserved cells plated at 12,000 cells per well for 24 h and the same cells plated at 4000 cells per well for 72 h. All fpKi data also had a standard error mean of less than 0.15.
Scatter Plot
Week FIG. 2. A graphical representation of the human histamine H1 receptor data for 6 test compounds over a 20-week time period. Data were generated using cryopreserved cells plated at 12,000 cells per well for 24 h (white triangles) and the same cells plated at 4000 cells per well for 72 h (black circles). The thick black line is the running mean, and the 2 thinner lines are plus and minus 3 standard deviations from the mean, respectively.
Week less variable. The data generated within this study indicate that cryopreserved cells are no more or less variable than their continuously cultured counterparts. In our experience, the cryopreservation of cells and utilization of these protocols generally result in assays of similar signal size and Z′. Although there are exceptions to this, the alpha 1B assay clearly showed a reduction in signal and Z′ but maintained overall reliability and pharmacological equivalence. The other exception was the 5HT2B SH-SY5Y assay, where although over successful runs data could be generated with very good Z′, the signal size was very small, and this often led to complete assay failure where any alteration in conditions resulted in variance and an inability to define a significant difference between the maximum and minimum points of curves and unreliable data. Hence, this assay was sourced from continuously cultured cells for support of chemistry programs, and although this was significantly better than its cryopreserved counterpart, it is still very sensitive to alterations in cell culture or assay protocol, making it the most problematic of the assays listed here. Furthermore, we have seen other targets and cell types that have not produced identical pharmacology when trailed using cryopreserved cells, and hence they have not been used. However, we currently support >80% of 90 calcium-based assays within our screening portfolio from cryopreserved cells. For assays using cryopreserved cells plated at low-density (4000 cells/well) 72-h plating and high-density (12,000 cells/well) 24-h plating, the data were shown to be pharmacologically identical with similar variance. In addition, data generated for known histamine H1 receptor ligands were consistent with data from other laboratories. [15] [16] [17] [18] Similarly, data for the adrenergic alpha 1A and alpha 1B receptors also compare favorably with previously reported values. [19] [20] [21] [22] Collectively, the data indicate that multiple cell types and G-protein-coupled receptor assays are amenable to cell freezing and to assay generation from differing cell densities and time points. During the development of these assays, we also examined the use of these cells within 2 h of recovery following cryopreservation (data not shown). This was done by using a simple protocol of thawing and adding the cells directly into the load buffer for the FLIPR assay at the point of plating. A low-speed spin in a plate centrifuge to take the cells to the bottom of the plate then allowed reproducible dose-response curves to be generated for the rat 1 fibroblast cells at 20,000 cells per well, alpha 1A pEC 50 = 7.05, alpha 1B = 7.98. Other cell types gave some responses, but they were significantly reduced in signal size and pharmacology as compared with cells incubated overnight. Interestingly, the prolonged calcium signal was always reduced across cell types, suggesting that the freezing protocols have some effect on secondary calcium responses, perhaps due to reduced ion channel expression or activation. In contrast to this, the agonist responses generated from cells that had been incubated for 24 or 72 h prior to assay both demonstrated similar profiles, indicating consistent activation mechanisms. Hence, work with cell plates for less than 24 h was not continued for production screening. Within this report, we have concentrated on production of high-quality compound profiling assays using cells plated at 24 and 72 h to increase flexibility and to allow assays to be conducted on a Monday without the need for cells to be manipulated over the weekend. However, we have no doubt that slight manipulation of these protocols could allow assays to be generated at further time points. For example, we have run the 5HT SH-SY5Y assays from cells 48 h following plating and generated identical pharmacology (data not shown). We would advise a note of caution, however, as we have not extended the plating time beyond 72 h because we have little requirement for this, but also because of contamination issues during development of these assays. The low-density plating and extended time period necessitate highquality cell culture and subsequent incubator sterility.
Our results summarize the use of cryopreserved cells within a compound profiling environment. Although a limited data set is used to illustrate each assay, these data sets contain subsets of both related and diverse chemical series; furthermore, the individual assays examined have now been run over an extended time period with hundreds of compounds being investigated each month in each assay, clearly demonstrating a potential application within an iterative compound profiling environment. Our experience is that where cryopreserved cells can be used, they are at least as reproducible and reliable as continuously cultured cells. In addition, they have the significant benefits of being able to make exactly the right number of plates the day before the assay is required, providing greater flexibility and less overproduction of cells. We have also demonstrated that by simple modification to seeding densities and plating times, reliable assays can be generated to allow profiling on any day of the working week. The low-density plating also allows precious reagents to be used more efficiently in the generation of higher plate numbers from the same frozen reagent. The data described validate the methods used to prepare, store, and assay these cells.
